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THE ROLE OF IRAK-1 TRANSCRIPTS IN SEPSIS 
by 
Adithya Subramanian Sahasranamam 
Sepsis is a complex, life-threatening syndrome that can lead to systemic organ failure and 
dysfunction. Its high morbidity and mortality rates makes it a critical global health issue. 
The primary factors at play during sepsis are abnormal inflammation and a lack of oxygen 
supply to the tissues and muscles. The toll-like receptors play a crucial role in eliciting 
innate immune in response to infection, primarily through the interleukin-1 receptor-
associated kinase (IRAK) pathways. Disturbances in the homeostasis of IRAK signaling 
cascades can lead to immune dysfunction. n this paper, we review the molecular 
mechanisms of IRAK-1, an important mediator of TLR-induced inflammation and 
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Systemic inflammatory response syndrome (SIRS) is a generalized immunological 
response against a vast range of pro-inflammatory pathologies, including infection, injury, 
trauma, and burns. SIRS is often characterized by significant changes in the body 
temperature and the onset of tachycardia, rapid breathing, and abnormalities in white blood 
cells (WBCs) and red blood cell (RBCs) counts and can give rise to systematic multi-organ 
dysfunction. When the onset of infection causes SIRS, the phenomenon is known as sepsis. 
Sepsis is a life-threatening inflammatory response that can give rise to systematic multi-
organ dysfunction and failure caused by either trauma or infection. 
Despite modern advances in elucidating the pathophysiology of sepsis, the 
condition remains one of the primary causes of mortality and morbidity in intensive care 
units (ICUs) worldwide. Current estimates suggest that sepsis affects more than 30 million 
people and accounts for more than six million deaths per annum worldwide. Based on the 
Surviving Sepsis Campaign data from 2012, 41% and 28.3% of reported deaths from sepsis 
occurred in Europe and the United States, respectively [1]. The study also found sepsis to 
be the most expensive health care condition in the United States annually, setting back 
American hospitals by USD 20 billion in 2011 alone [3]. These financial and mortality 
costs make the investigation of sepsis's molecular mechanisms a top priority to elucidate 
possible immune modulation therapies to more effectively treat patients afflicted by sepsis. 
Severe sepsis is when the host's reaction to infection causes a systemic cascade of 
organ failures in a manner referred to as septic shock [1-6]. Sepsis is believed to cause 
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organ failure through the uncontrolled upregulation of systemic immune responses. 
However, in light of medical and scientific advancements, ICU survival rates have 
improved, which led to the detection of the immunosuppression phase in the later stages of 
sepsis pathophysiology, ultimately explaining the high mortality rates. This syndrome was 
termed "compensatory anti-inflammatory response syndrome" (CARS) by Bone in his 
1996 paper [4]. Similar to SIRS, CARS is a complex immune system response to severe 
infection; however, CARS is believed instead to be a condition marked by systematic 
inhibition of the immune system that restores homeostasis after the period of extreme 
inflammation. This led scientists and medical professionals to use the terms SIRS and 
CARS to differentiate the host's pro- and anti-inflammatory responses to a broad range of 
infectious and noninfectious stimuli [6–9].  
While initial studies categorized CARS as the phase that appears at the end of or 
even after SIRS, researchers have since found evidence of pathways that support the idea 
that CARS is not a part of SIRS. Instead, CARS may exist entirely separately from SIRS 
and encompass an additional set of cellular and molecular interactions and pathogenesis 
pathways different from those of SIRS. However, CARS may also significantly influence 
sepsis and lead to adverse outcomes. Earlier studies of the pro-inflammatory phase of 
sepsis have helped to improve survival rates in the ICU. The emergence of an 
immunosuppression phase in the later stages of sepsis pathophysiology often left the 
patient vulnerable to secondary infections, which could explain the high mortality rates 
[10]. Indeed, later studies revealed that the anti-inflammatory responses elicited by CARS 
induce a severe immunosuppressed state wherein the immune system cannot recover 
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despite eradicating pathogens from the body, which, as a phenomenon, has been termed 
“immune paralysis” [5].  
Modern advances have reduced the rates of deaths occurring during sepsis's initial 
stages as homeostasis is reestablished early on in the disease's pathophysiology. However, 
those patients who fail to achieve homeostasis during the early phases of SIRS/CARS enter 
a state marked by high mortality and morbidity rates, typically exhibiting severe weakness, 
malnutrition, chronic infections, and cognitive decline, which has come to be known as 
chronic critical illness [10–13].  
Data from 2009 indicate that the annual health care costs for patients with chronic 
critical illness exceeded $20 billion. The majority of these patients (> 60%) were admitted 
with a sepsis diagnosis [12], and only 20% were ultimately discharged home; more than 
40% were discharged to long-term acute care and skilled nursing facilities [11, 12], while 
30% died in the hospital [12].  
Due to its associated high mortality rates, CARS soon became a target for immune-
modulating therapies [14]. However, despite extensive preclinical research into possible 
immunomodulatory therapies for CARS, not many treatment solutions to date have been 
implemented [15]. Later studies found that, during CARS’ immunosuppressive phase, an 
increase in the levels of pro-inflammatory cytokines such as C-reactive protein (CRP), 
interleukin (IL)-6, IL-1, and tumor necrosis factor (TNF) [14, 16] occurred, together with 
a substantial rise in the recruitment and release of immature myeloid leukocytes associated 
with chronic inflammation [17]. These studies have supported the design of a more fluidic 
model of sepsis with simultaneous inflammatory and immunosuppressive processes. This 
 
 4 
eventually led to the replacement of the traditional SIRS/CARS model with the concept of 
persistent inflammation–immunosuppression catabolism (PICS) [6].  
PICS is characterized by a low but constant, chronic state of inflammation that 
paralyzes the host's immune system while exerting drastic catabolic effects on the body 
mass’ nutritional intervention [7, 13]. The key adaptive immune features that once typified 
CARS such as immune and metabolic failure, increased T-cell suppression, and inhibition 
of  proinflammatory signaling are now thought to be a part of PICS [1, 22, 23, 28–33]. The 
definitions and diagnostic criteria for sepsis and PICS are depicted in Table 1.1. 
While the etiology or pathophysiology of PICS has not been completely elucidated, 
extensive studies on pro-and anti-inflammatory cytokines and chemokines have revealed 
the sheer breadth of sepsis and its many modes of action. Recently developed controversial 
theories suggest that the role of endotoxins and immunosuppressive SIRS medication 
might be secondary to the role of endogenous molecules like catecholamines [18, 36], 




Table 1.1  The Terminologies and Definitions of Sepsis 
Term Definition 
Infection 
The invasion of an organism by a pathogen that elicits a pro-
inflammatory response. 
Sepsis 
An extremely dysregulated immune response from the host in 
response to infection. 
Onset of Sepsis 
Observation of dysfunction in a new organ, away from the 
original site of infection. 
Sequential Organ 
Failure Assessment 
score (SOFA score) 
The SOFA score is used to track a patient's status by 
determining the extent and severity of a patient's organ function 
over time. It uses data from the Cardiovascular, respiratory, 
hepatic, renal, and neurological organ systems for calculation. 
Rapid bedside organ 
dysfunction score – 
qSOFA 
A quick test that suggests potential Organ dysfunction if at least 
two of the following is present: 
Altered Mental Status – Glasgow Coma Scale ≤ 14 
Systolic Blood Pressure ≤ 100 mmH 
Respiratory Rate 22 breaths per min  
Organ Dysfunction 
A significant change in the SOFA score by at least two points at 
a site remote from infection. 
Septic Shock 
A state of sepsis that elicits a cascade of profound changes in 
the vasculature, metabolism, cellular, and organ functions. 
PICS 
 
Critically ill patient Admission to the ICU > 14 days 
Persistent 
inflammation 
CRP > 50 μg/dL 
Retinol binding protein < 1 mg/dL 
Immunosuppression Total lymphocyte count < 0.80 
×109/L 
Catabolic state Serum albumin < 3.0 g/dL 
Creatinine height index < 80% 
Weight loss > 10%  
BMI < 18 during hospitalization  
Source: Mira, J. C., Gentile, L. F., Mathias, B. J., Efron, P. A., Brakenridge, S. C., Mohr, A. M., ... & 





THE MOLECULAR PATHWAYS OF SEPSIS  
   
The host's body initially promotes an innate pro-inflammatory response as a response to 
pathogens, which is arbitrated by antigen-presenting cells (APCs). These cells express 
pattern-recognition receptors (PRRs) on their surface, which can detect pathogen-
associated molecular patterns (PAMPs) expressed on a pathogen's surface or through the 
release of damage-associated molecular patterns (DAMP) as a result of tissue damage [34]. 
Upon recognition, the PRRs activate various receptors such as the nucleotide-binding 
oligomerization domain (NOD)-like receptors and Toll-like receptors (TLRs). The 
activation of these receptors causes a cascade of reactions across multiple pathways that 
promote the manufacture of pro-inflammatory cytokines and chemokines, which trigger 
second messenger cascades, resulting in amplified immune responses [35]. 
Cytokines and chemokines are crucial mediators of immune responses as they 
enable the recruitment of leukocytes to the site of infection/injury and increase the 
permeability of the endothelial vasculature, allowing for the localization of leucocytes [36, 
37]. Cytokines and chemokines also facilitate communication between immune cells and 
their mediators and among adipocytes, fibroblasts, and endothelial cells. Additionally, 
cytokines and chemokines allow for interactions between the various cascade systems 
responsible for eliciting immune responses to occur [38–41]. 
 The NOD-like receptor group aggregates to form larger protein complexes called 
inflammasomes [7]. These protein complexes play a vital role in the production and release 
of critical cytokines IL-1β and IL-18. They are also involved in the formation of caspases, 
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which are implicated in apoptosis [42]. These pro-inflammatory cytokines elicit leukocyte 
proliferation, upregulate chemokine expression and express tissue factor production, and 
induces the production of hepatic acute-phase reactants, which are important mediators 
produced in the liver during times of acute and chronic inflammation [43, 44].  
The name interleukin was suggested in 1979, which means "communication 
between leukocytes" [45, 46]. Many of these proteins are produced by and act on 
leukocytes, but cells from other tissues can also secrete them. They exert complex immune-
modulatory functions, including cell proliferation, maturation, migration, and adhesion 
[47-49]. 
During sepsis, these immune responses are amplified, leading to damage and death 
of tissues and cells. Recent studies that have analyzed the association between IL-18 levels 
and mortality [50–52] suggest the role of inflammasomes and autophagy as potential 
targets in the treatment of sepsis. 
 
2.1 Toll-Like Receptors  
TLRs are a type of PRR expressed on APCs. These TLRs are thought to play a very crucial 
role in the induction of innate immunity. This family of type I transmembrane receptors 
was initially found in drosophila and were confirmed to possess an extracellular leucine-
rich repeat domain and a highly conserved intracellular Toll/IL-1 receptor (TIR) domain 
across plants and animals. This TIR domain enables interactions between proteins and has 
been shown to play a vital part in the evolution of immunity.  
In mammals, scientists have uncovered ten different kinds of TLRs, with each one 
playing a tailored role in innate immunity. These TLRs recognize highly conserved PAMPs 
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as ligands and have exceptionally low specificity as compared to antibodies. This low 
specificity of these receptors allows them to recognize a plethora of microbial products. 
Due to their low ligand specificity, TLRs have become a topic of great scientific interest 
[53–57].  
Figure 2.1  Toll-like Receptors possess an affinity for a diverse range of microbial 
ligands. This feature enables them to recognize a wide variety of PAMPs/DAMPs. Upon 
recognition of these ligands, TLRs initiate downstream pro-inflammatory responses that 
lead to the production and recruitment of pro-inflammatory cytokines.  
 
Source: Medzhitov, R. (2001). Toll-like receptors and innate immunity. Nature Reviews Immunology, 1(2), 
135-145. 
 
Although TLRs’ complete workings have not yet been elucidated, recent data 
suggest that they often work as dimers. While most form identical homodimers, some form 
heterodimers, with each dimer maintaining a unique affinity for ligands. These PRRs 
depend upon accessory proteins to aid in their binding with PAMPs. In particular, TLR4—
the most studied mammalian TLR—plays a crucial role in recognizing the PAMP 
lipopolysaccharide (LPS), which is only produced by prokaryotes like Gram-negative 
bacteria. TLR4's recognition of LPS requires MD-2, a small protein that lacks a 
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transmembrane domain, and CD-14, a high-affinity LPS receptor often expressed on 
macrophage surfaces. CD-14 and LPS-binding protein (LBP) present LPS to MD-2. When 
these TLRs are activated, they recruit adapter molecules from the cell's cytoplasm that 
initiate signaling cascades like MyD88 [58–60] and Toll-interacting protein (TOLLIP), a 
protein kinase, IL-1 receptor (IL-1R)–associated kinase (IRAK) [58, 59, 61]; and another 
adaptor, TNF receptor-associated factor 6 (TRAF6) [58, 59, 62]. Recent studies have 
confirmed the crucial roles of these adaptor molecules in regulating innate immunity 
through targeted deletions of genes of the adaptor molecules [63–65]. Other studies have 
reported that MyD88-deficient mice fail to produce pro-inflammatory cytokines like IL-1, 
TNF, IL-6, and IL-12 when stimulated with ligands of the TLR systems, respectively [60, 
65–68]. However, later detailed analyses have revealed the existence of a MyD88-
independent pathway called the TRIF-dependent pathway that promotes the transcription 
of pro-inflammatory cytokines as well as trans-inflammation through the production of 
interferons (IFNs). All TLR families except TLR3 use MyD88-dependent pathways. 
Further studies of MyD88 pathways have revealed an important regulatory adaptor protein 
family, the IRAK family of kinases. 
 
2.2 Interleukin-1 Receptor-Associated Kinases 
Among the many genes involved in the TLR-signaling cascade, Interleukin-1 receptor-
associated kinase 1 (IRAK-1) has been portrayed as an essential modulator of 
inflammation. IRAK-1 belongs to the interleukin-1 receptor (IL-1R) associated kinase 
(IRAK) family, [69] which orchestrates the pro-inflammatory responses to pathogenic 
invasions through signal transduction and mediation of the toll-like receptor (TLR) and 
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interleukin-1 (IL-1) signaling pathways [25]. These IRAKs serine-threonine kinases are 
expressed on the membranes of various immune cells such as dendritic cells, neutrophils, 
macrophages, and other non-immune cells like the epithelial and endothelial cells and 
fibroblasts) [70]. Together with the Interleukin-1 receptors (IL-1Rs), these TLRs form a 
receptor superfamily, called the "interleukin-1 receptor / toll-like receptor superfamily". 
All TLR family members exhibit the TIR (toll-IL-1 receptor) domain, a highly conserved 
domain homology that promotes acute inflammation and other additional adaptive immune 
responses.  
When ligands bind to the TLRs, it recruits the adaptor protein MyD88. MyD88 
possesses a TIR domain (Toll and IL-1-receptor homology domain to the intracellular TIR 
domain of TLRs. The TIR domain is connected with the death domain (DD). Upon TLR 
activation, the DD of MyD88 interacts with the DDs of the IRAK family of kinases and 




Figure 2.2  The TLR-induced NF-κB signaling is primarily mediated by IRAKs.  
 
Source: Medzhitov, R. (2001). Toll-like receptors and innate immunity. Nature Reviews Immunology, 1(2), 
135-145. 
 
This TLR–nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) 
transduction plays a vital role in governing the initiation of innate pro-inflammatory 
immune responses by increasing the expression of pro-inflammatory mediators such as IL-
6, TNF, HMGB1, adhesion molecules, and chemokines that are implicated in sepsis-
induced organ dysfunction [71–74]. Studies on mice have shown that macrophages 
deficient in IRAK-1 express an inadequate pro-inflammatory response to TNF in response 
to LPS-induced sepsis and are thereby resistant to LPS lethality [75]. However, this makes 
the mice also very vulnerable to infections by Gram-negative bacteria [76].  
TLR-mediated cell signaling in immunity is negatively regulated by another vital 
member of the IRAK family, known as IRAK-M (or IRAK-3) [77–79]. Unlike IRAK-1, 
IRAK-M does not possess kinase activity but instead regulates signaling through MyD88-
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dependent TLRs [79]. Initially, the IRAK-M expression was thought to be present only in 
monocytes; however, recent studies have shown that it is present in both hematopoietic and 
nonhematopoietic cells. IRAK-M is primarily involved in inflammatory and anti-microbial 
responses. IRAK-M determines the levels of endotoxin tolerance, thereby dictating the 
magnitude of pro-inflammatory sepsis-induced changes [79–83]. Recent studies indicate 
that IRAK-M mediates macrophages’ tolerance to LPS and the tolerance level in 
nonhematopoietic cells such as biliary epithelial cells [79, 83]. 
Patients suffering from sepsis also appear to express higher IRAK-M levels in their 
blood monocytes, with some studies indicating that IRAK-M levels were highest during 
the most profound blunting of LPS-induced cytokine responses. The relatively high 
expression of IRAK-M is associated with adverse clinical outcomes in sepsis patients [82, 
84]. While the mechanisms accounting for IRAK-M–based endotoxin tolerance and the 
negative regulation of inflammation are not entirely known, they are believed to be 
associated with impaired TLR-mediated activation of both NF-κB and mitogen-activated 
protein kinase (MAPK)-dependent genes [85–87]. It is thought that IRAK-1M represses 
IRAK-4 activation, leading to a subsequent blockage of IRAK-1 phosphorylation [79]. 
Meanwhile, IRAK-1 hyperphosphorylation results in decreased protein stability, providing 
a potential mechanism by which to regulate IRAK-1 activity [88]. 
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Figure 2.3  TLR4 mediates the recognition of the antigen LPS. The TLR4 pathway is 
responsible for initiating an anti-microbial inflammatory response via the NF-κB, Map3k, 
or the IRF3 pathways. 
 
Source: File: Toll-like receptor pathway.svg. (2020, September 29). Wikimedia Commons, the free media 




2.3 Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B-Cells (NF-κB) 
NF-κB is a protein complex that is highly conserved and expressed in almost all animal 
cells. This protein complex has been labeled as a "rapid-acting primary transcription 
factor" as it is found in an inactive state but does not require protein synthesis for its 
activation [89]. This allows NF-κB to act rapidly and function as the first responder to 
harmful stimuli responsible for both the innate and adaptive immune responses [90]. 
NF-κB can be activated by a wide variety of stimuli, such as TNF, IL-1β, and 
reactive oxygen species (ROS), and through the stimulation of a wide variety of cell-
surface receptors such as TLRs [89]. All TLRs other than TLR3 use MyD88 and are 
dependent upon IRAK-1 for activation. Following its activation, NF-κB translocates into 
the cell nucleus, promoting the transcription of a wide variety of genes involved in 
inflammation, cell survival, and cell proliferation. Any disturbance of the normal 
expression and function of NF-κB can lead to cancer and inflammatory and autoimmune 
diseases, together with greater vulnerability toward microbial infection and sepsis. 
 
2.4 The Complement System 
The complement system consists of small proteins synthesized by the liver that circulates 
in the blood as zymogens or inactive precursors. When the system is activated, proteases 
in the system begin to cleave proteins, releasing cytokines that initiate a cascade of 
zymogen cleavages that are highly amplified by each successive enzymatic reaction, 
resulting in the rapid and exponential generation of a large complement inflammatory 
response [91].  
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These responses result in the recruitment of phagocytes to the site of the 
inflammation, the stimulation of said phagocytes to eradicate foreign material, and the 
activation of the cell-killing membrane attack complex. The complement system can be 
activated by any of the following three pathways: the classical pathway (CP), the 
alternative pathway (AP), and the lectin pathway (LP) [92]. These three pathways all 
converge at the complement protein C3 convertase and share a common cascade from C5 
to C9, which leads to the formation of the cell-killing membrane attack complex and its 
subsequent pursuit of target cells. This is complemented by the release of chemo-attractants 
(C3a and C5a) to aid in the recruitment of inflammatory cells [93]. 
The classical pathway uses the complement component 1q (C1q) as the PRR; C1q 
is a part of the C1 complex together with the proteases C1r and C1s. When C1q binds to 
the antigen-antibody complexes together with immunoglobulins G and M or apoptotic cells 
or structures on microbial cells, the proteases activate, cleaving C4 into C4a and C4b. C2 
reacts with C4, creating the C4bC2a enzyme (C3 convertase) [94]. 
The PRR used in the lectin pathway is the mannose-binding lectin (MBL) or 
ficolins, which binds to apoptotic host cells and can also recognize and bind with 
carbohydrates. Such PRRs are similar to the CP pathway but are bound with MBL‐
associated serine proteases, which cleave C4 and C2 to yield C3 convertase [95].  
The AP uses C3 as its central molecule. C3 is cleaved by CP/LP convertases or C3 
(H2O) formed from B (fB) binding. This cleavage of C3 exposes a thioester moiety in C3b, 
which allows for binding with surfaces [96]. fB then undergoes cleavage by the serum 
protease factor D (fD), producing AP C3 convertase C3bBb [or C3(H2O) Bb]. The AP C3 
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convertase is stabilized by properdin, which allows for the recognition of several PAMPs 
and DAMPs, initiating a complement response [97]. 
 
Figure 2.4  The Complement system mediates the activation of phagocytes in response to 
inflammation. 
 







MULTI-ORGAN FAILURE IN SEPSIS 
  
3.1 Organ and Tissue Dysfunction 
The primary pathophysiology of sepsis occurs through the combined effect of 
hyperinflammatory humoral and/or cellular responses to the presence of PAMP/DAMP by 
humoral or innate APCs. This causes the APCs to trigger a one-to-many pro-inflammatory 
signaling cascade that leads to leucocyte recruitment. Although the pro-inflammatory 
response is controlled under normal conditions, sepsis induces a hyperinflammatory 
response that leads to a barrage of pro-inflammatory activity, which can culminate into 
multiple organ failure. 
 
3.2 Cardiovascular Dysfunction  
The primary cause of sepsis-induced organ failure and tissue dysfunction is a reduced 
supply of blood flow and oxygen to organs and tissues. Sepsis correlates with a broad 
spectrum of cardiovascular abnormalities that can lead to hypoperfusion, which is the 
initial hemodynamic profile of severe sepsis brought on by cardiogenic, hypovolemic, and 
distributive shock. In the early stages of sepsis, multiple changes occur in sepsis patients' 
vascular beds that are primarily elicited by the action of inflammatory cytokines such as 
TNF and IL-1 on the endothelial layers [98–100]. 
During sepsis, there is an overwhelming and dysregulated pro-inflammatory 
response that causes a massive buildup and release of pro-inflammatory cytokines like IL-
1α, IL-1β, TNF, and IL-6. These cytokines interact with endothelial cells at the site of the 
injury to dilate the capillaries at the vascular bed and increase their permeability, enabling 
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the accumulation and flow of platelets and WBCs to handle repairs and infection at the site 
in question. IL-1 is composed of two genes: IL-1α and IL-1β. Upon its release, both IL-1α 
and IL-1β bind to the IL-1 receptors (IL-1R) on the walls of the vascular endothelium and 
promote the breakdown of the endothelium and its junctions by triggering the MyD88 
signaling cascade [101, 102]. While these processes are regulated during normal 
conditions, the lack of immune homeostasis in sepsis leads to enhanced endothelial 
dysfunction. Endothelial dysfunction is marked by increased vasodilation and vascular 
capillary permeability. This results in the leakage of cytokine-rich fluid into the 
peripheries, causing edema and compromising vascular volume and blood pressure, 
resulting in hypotension and hypovolemia. Furthermore, the lack of a functional 
endothelial layer allows for microbial invasion deeper into the host, enabling the pathogens 
to potentially disturb regulatory mechanisms and ultimately cause dysfunction of remote 
organs [103]. 
In response to increased cytokine activity, neutrophils, fibroblasts, APCs, and 
macrophages are recruited to the site of the injury in concert with the production of 
secondary pro-inflammatory mediators by both macrophages and mesenchymal cells. TNF 
stimulates macrophages to produce IL-6, an interleukin with both pro-and anti-
inflammatory properties [104]. IL-6 is released following a spike in TNF levels and acts as 
a signal for tissue damage; it is primarily involved with the mediation of the acute-phase 
response [105, 106], which triggers a systemic cascade that promotes leukocytosis, 
combined with symptoms of fever along with the release of Hepatic acute-phase proteins 
(APPs) such as CRP, complement components, fibrinogen, and ferritin [107]. These 
hepatic proteins are vital markers of inflammation and tissue damage and are primarily 
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associated with the recruitment of peripheral leukocytes, circulating neutrophils, and their 
precursors. These proteins also play a crucial role involved in coagulation in response to 
endothelial damage [100-107].  
Mesenchymal cells such as those of the subendothelial layers and fibroblasts often 
have a repressed expression of Tissue Factor (TF). Either TNF stimulation of monocytes 
or the exposure of subendothelial cells in response to tissue injury can lead to the 
expression of TF, which binds with factor VII, causing the activation of the intrinsic 
coagulation cascade. During this coagulation cascade, prothrombin, a zymogen of 
thrombin, gets cleaved into thrombin, a powerful activator of platelet cells (thrombocytes) 
[108]. Thrombocytes are primarily involved in the homeostasis of injury and use oxygen 
radicals called ROS for signaling, which possesses powerful anti-microbial and antiviral 
properties to damage the DNA, RNA, and proteins of bacteria and viruses [109–112].  
Thrombocytes release ROS into the bloodstream to signal for more thrombocytes. 
However, in the case of sepsis, dysregulation of the immune response leads to an 
accumulation of thrombocytes at the site of the injury, triggering an autoimmune response 
that damages the host's genetic and protein materials [113]. This can lead eventually to the 
formation of cancerous lesions [114]. 
ROS induces chronic inflammation by the induction of cyclooxygenase-2, 
inflammatory cytokines such as TNF, IL-1, IL-6, and IFNs and promotes the transcription. 
This production of IL-1, TNF and IFN promotes the recruitment of neutrophils to the site 
of inflammation [115, 116]. 
Neutrophils are phagocytes that are considered the first responders to injury and 
infections. Neutrophils are primarily produced in the bone marrow and migrate towards the 
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site of injury via chemokine chemotaxis. They promote phagocytosis through the release 
of ROS and the formation of extracellular traps called neutrophil extracellular traps (NETs) 
[117]. Activated thrombocytes promote the formation of NETs and have been implicated 
in the extravasation of neutrophils across the endothelium [118, 119]. This process has 
been associated with the release of TNF and nitric oxide (NO). NO is a potent vasodilator, 
among its many roles [120, 121]. Together with NO, TNF upregulates the expression of 
adhesion molecules like selectins and integrins on the endothelial surface, which promote 
the binding of leukocytes with the endothelium, allowing them to cross over into the tissue 
[120–122]. 
Excess levels of ROS can elicit a state of constant oxidative stress in erythrocytes 
and cause them to recruit leukocytes even after the pathogenic threat has been eradicated. 
This state of constant oxidative stress often results in a positive feedback loop that 
promotes pro-inflammatory and homeostatic repair. This constant state of oxidative stress 
elicits profound morphological changes in the vasculature and the vascular bed of a sepsis 
patient through persistent endothelial damage through the action of cytokines, ROS, 
leukocyte extravasation, and the formation of multiple thrombi along the vasculature [123]. 
Various studies have demonstrated the impact of the role of inflammation in 
coagulation and the role of coagulation in the pathophysiology of sepsis [124, 103]. Due 
to the lack of functional vascular blood–tissue barrier, there is a leakage of cytokine-rich 
blood into the periphery, which causes edema. This condition is actually made worse by 
the onset of rapid coagulation. The thrombi formations often restrict the flow of blood, 
promoting localized cell death and tissue damage due to hypoxia [103]. This formation of 
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multiple thrombi across the arteries and veins is referred to as disseminated intravascular 
coagulation (DIC) [125].  
DIC is a serious effect of sepsis that can lead to rapid multiple thrombi formation 
along the arterial and venous pathways, causing severe obstruction of blood flow. This 
condition rapidly uses up the clotting proteins and factors in the blood, causing an inability 
to form clots; this state can increase one’s susceptibility to bleeding and is known as 
hemorrhagic diathesis [125, 126]. 
Clinical studies have associated DIC with the development of multi-organ 
dysfunction, leading to mortality in patients with sepsis [127]. DIC occurs in approximately 
83% of the patients with bacterial sepsis [128]. The prognosis of DIC and the associated 
mortality rates depend on the severity of sepsis and thrombosis. A recent study suggests a 
47.7% mortality rate for DIC, with some statistics purporting higher mortality rates among 
African American (52%) and Native American (57%) populations [129], suggesting 
possible genetic predispositions towards less favorable outcomes during DIC and sepsis in 
certain groups. 
Various studies have implicated the roles of TLRs in heart disease and failure. 
TLR4 plays a central role in promoting myocardial inflammation, primarily mediated via 
the NF-κB pathway [130]. The activation of the NF-κB pathway in cardiomyocytes results 
in the expression of various inflammatory mediators such as TNF, IL-6, IL-1, and NO. The 
chronic release of these pro-inflammatory cytokines promotes interstitial fibrosis and 
collagen deposition in the non-infarcted zone leading to ventricular dysfunction [131, 132]. 
This affects the heart’s ability to pump blood to the periphery. 
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Furthermore, as a result of clotting and blood loss, the volumetric blood return to 
the heart is severely compromised, which results in a state of cardiovascular dysfunction 
called myocardial depression (MD) categorized by a lower decreased stroke volume and 
ejection fraction. The heart responds to this state of hypoxia with a tachycardia response 
with increased ventricular distensibility. Despite the intense distensibility of the right 
ventricle, the reduced arterial resistance [24] leads to a decreased volumetric return of 
blood at the left auricle, which facilitates the depression of the auricular contractility. There 
is also leakage in and out of the myocardial sections, affecting the ventricular ability. 
Furthermore, NO has been implicated given its role as a cardiac dilator; NO induces the 
muscle cells to relax and hyperpolarize, preventing their response to vasoconstrictors and 
thus perpetuating hypotension.  
This state of relaxation combined with the arterial and venous dilation caused by 
the pro-inflammatory cytokines results in a state marked by hypotension and distributive 
shock [10], the latter of which causes improper perfusion of blood and hypoxia all across 
the body. These initial stages of inflammation followed by a lack of proper circulation are 
the primary cause of systemic organ failure in patients with sepsis.  
 
3.3 Hepatic Dysfunction 
Ischemic hepatitis or shock liver is characterized by acute liver injury due to inadequate 
blood flow and hypoxia. This condition primarily occurs as a result of cardiac failure and 
septic shock. 
The liver plays an important role in maintaining normal metabolic, hormonal, and 
host-defense activities; ensuring overall systemic homeostasis; and regulating coagulation. 
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It is responsible for clearing bacterial and toxic materials from the bloodstream [133]. 
Animal models show that more than 60% of bacteria injected intravenously are trapped in 
the liver by 10 minutes post-injection [134]. The liver is also responsible for the clearance 
of endotoxins like LPS from the bloodstream [135]. Various kinds of hepatocytes like 
Kupffer cells (KCs), liver sinusoidal endothelial cells (LSECs), and stellate cells are 
involved in microbial clearance. Given the crucial roles the liver plays in metabolism and 
homeostasis, the liver is perfused by 25% of the cardiac [136].  
Studies have shown that ongoing inflammation and hypoperfusion can cause liver 
damage and failure. Clinical statistics suggest that hepatic dysfunction is an early sign of 
sepsis, with a mean incidence rate of 39.9%, and is a risk factor that has been associated 
with poor outcomes [137]. While the exact pathophysiologies of liver dysfunction and 
failure are yet to be fully understood, liver dysfunction is often associated with chronic 
inflammation, hypoxia, and initial tissue hypoperfusion, either through alterations to the 
hemodynamic profile or through a direct or indirect assault on the hepatocytes—or a 
combination of both. 
KCs are the first line of defense in the liver. The liver harbors approximately 80% 
of all macrophages in the human body as resident KCs [138]. Upon their activation by 
TLR4, KCs produce high levels of pro-inflammatory cytokines like TNF, IL-1, IL-6, and 
IFN-γ along with secondary mediators of tissue injury, e.g., NO and ROS [48]. These 
cytokines then transduce intracellular signals, causing hepatocytes to lower bile transporter 
expression and function [139-141] and triggering a shift in hepatocyte metabolic pathways, 
promoting inflammation and repair responses, which are responsible for an increase in the 
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synthesis of APPs mediated predominantly by IL-6, which results in the formation of a 
procoagulant phase [142]. 
Another major cytokine responsible for hepatic dysfunction is IL-18, which is 
secreted by KCs in response to LPS stimulation. IL-18 triggers the release of , IFN-γ which 
promotes HC apoptosis, and also increases TNF levels. [143]. Furthermore, IFN-
γ upregulates TLR4 expression [144], which can further promote inflammation and the 
adhesion of neutrophils to sinusoidal endothelial cells, promoting thrombi formation in the 
hepatic sinusoids and impairs liver microvascular perfusion [145] through TNF- and IL-1–
induced migration of leukocytes into the liver, causing hepatic damage. 
As damage to hepatocytes spreads, the liver’s ability to transport bile acid and 
bilirubin is damaged. There is a profound alteration in bile acid bilirubin's transportation 
into the hepatic canaliculi, which causes cholestasis as the bile fluid leaks within hepatic 
tissue. Cholestasis has been linked to well-defined apoptosis in rat hepatocytes and is 
thought to be high in pro-inflammatory DAMP-like molecules. Cholestasis is thought to 
promote inflammation [146]. 
 
3.4 Pulmonary Dysfunction  
Acute lung injury (ALI) can be defined as a hypoxic failure of the respiratory system due 
to inflammation. It is characterized by inflammatory injury to the alveolar-capillary barrier, 
along with neutrophil extravasation and protein-rich edema fluid leakage into the alveolar 
spaces, significantly affecting the lungs' ability to engage in gas exchange. This can be 
caused by direct damage to the alveolar tissue or through extrapulmonary causes like 
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sepsis. ALI, in its worst phase, is known as acute respiratory dysfunction syndrome 
(ARDS).  
The primary cause of ALI/ARDS is endothelial dysfunction due to inflammation 
and neutrophil extravasation into the alveolar spaces. This onset of inflammation is 
primarily the result of resident macrophages called alveolar macrophages. These 
macrophages are the first line of defense in the lungs and play a central role in orchestrating 
inflammation upon activation via the TLR4/NF-κB pathway, which then promotes the 
release of pro-inflammatory cytokines like cytokines (e.g., TNF and IL-1β), chemokines 
(e.g., IL-8), and thrombin, together with the actions of a plethora of mediators like 
proteases, ROS, and NO that support the vasopermeability and disintegration of the 
endothelium. This results in the leakage of protein-rich fluid extravasation into the 
pulmonary interstitium and alveolar spaces. The resultant edema reduces the alveolar 
volume and gas capacity available for gaseous exchange, culminating in a reduced 
exchange of oxygen and CO2 at the blood–alveolar barrier. 
The Alveolar Macrophages (AMs) also interact with other cells like the epithelial 
cell lymphocytes and mesenchymal stem cells [147-149] using paracrine methods. AMs 
stimulate the recruitment of neutrophils and dendritic cells through the secretions of TNF 
and IFN. Neutrophils clear pathogens by phagocytosis and by releasing NETs. NETs are a 
complex system of anti-microbial components that trap and kill bacteria [149] due to the 
release of NET-associated components (NET-ACs), which are primarily made up of anti-
microbial peptides [150, 151]. The majority of NET-ACs are considered to be DAMPs, 
and their excessive release results in inflammatory responses that can lead to cell death, 
inflammation, and organ failure [152–157]. NETs amplify the pathophysiology of sepsis 
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through multiple pathways: among others, they induce endothelial and epithelial cell 
damage, provide [155] a scaffold for platelet binding, and promote thrombosis in sepsis 
[156]. This inflammation/damage site serves as an entry point for macrophages and 
facilitates the activation of dendritic cells. NETs trigger macrophages to produce cytokines 
[157] such as IL-1β by releasing DNA and serine proteases (among NET-ACs). 
Furthermore, the combined activation of neutrophils and thrombocytes results in the 
promotion of endothelial and tissue damage. Preclinical studies have reported that blocking 
the formation of neutrophil–platelet aggregates slow down ARDS development [154, 157- 
160]. 
Several neutrophil-derived mediators, including proteases, cationic peptides, ROS, 
and matrix metalloproteinases, appear to be important in triggering an increase in epithelial 
permeability caused by neutrophils and may be important in alveolar epithelial injury 
[161]. The role of oxidants derived from neutrophils and other sources has been explored 
in several experimental studies [162]. 
Neutrophils and APCs also induce the apoptosis of distal alveolar type 2 epithelial 
cells, which maintain lung fluid homeostasis through ion transport and also produce the 
pulmonary surfactant (PS), a crucial substance that coats the surface area of the inner lungs 
to minimize the surface tension of the alveoli. Damage to these cells leads to the 
development of an acute exudative phase that results in significant impairment of lung 
mechanics and gas exchange, which leads to hypoxia and hypercapnia (excess CO2) [163]. 
Some endotoxins like LPS are recognizable by both the complement system, the 
AP, and the TLR4 receptors. Exposure to PAMP/DAMP triggers the production of and 
releases pro-inflammatory peptides such as C3a and C5a. C5a elicits ROS production from 
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neutrophils. Through ROS-induced IL-1 and TNF release, the TLRs activate, resulting in 
alveolar damage and inflammation [164]. C5a can also promote NET formation [165].  
The blood supply to the site of injury is usually restricted due to increased 
thrombosis formation caused by the primary injury. Moreover, at sites of inflammation, O2 
consumption is elevated due to increased demand from immune cells. Furthermore, a 
reduced supply of metabolic substrates by blood clots, compression of blood vessels, and 
atelectasis of the lung contribute to tissue hypoxia during inflammation. The leakage of 
protein-rich fluid extravasation into the pulmonary interstitium and alveolar spaces results 
in decreased gas capacity and interrupts the exchange of oxygen and CO2 at the blood–
endothelial barriers. All these issues collectively support the onset of hypoxia, 
hypoglycemia, and acidosis, which lead to increased production of free radicals and ROS 
[166, 167].  
The lungs showcase one of the most severe pathophysiologies to arise from sepsis 
in the form of ARDS. Due to persistent and chronic expression of pro-inflammatory 
cytokines, there is a disruption of the fluid mechanics between air and blood at the alveolar–
blood barrier as a result of extensive damage by both neutrophils and alveolar 
macrophages. Hypoxia results in hyperacidosis due to increased levels of lactate in the 
blood. This triggers the release of ROS [169], which further exacerbates the damage. The 
combination of inflammation, hypoxia, lactic acidosis, and improper perfusion facilitates 






3.5 Immunosuppression in Sepsis  
During PICS, inflammation is marked through high levels of acute-phase proteins, 
neutrophilia, and the release of immature myeloid cells. While the mechanisms behind the 
immediate inflammatory response of PAMPs and DAMPs have been elucidated, the 
etiology behind the chronic and persistent inflammation in PICS remains unclear. It has 
been hypothesized that PICS follows the same pathways as an immediate inflammatory 
response. The alarmins "Danger" signals might arise from one's own injured tissue or organ 
structure. It might as well be the histones, nucleosides, or DNA [166]. The presence of 
these "Danger" molecules can trigger a variety of immune signaling pathways through 
various receptors and in various cell types, including immune, epithelial, and endothelial 
cells [170, 171]. As a result, the production of both pro-and anti-inflammatory cytokines 
and reactive oxygen and nitrogen species results in tissue wasting and apoptosis [12]. There 
have also been alternative theories as to why the pathophysiology of PICS accounts for 
opportunistic infections arising from viral reactivation [172], suggesting changes in gut 
microbiota, or by mechanically induced trauma caused by mechanical ventilation or 
administration of catheter. As sepsis progresses, one can almost definitely see a trend 
towards increasing cases of opportunistic infections, coupled with the compounding 
complexity of the interactions between the paradoxical states of inflammation and 
immunosuppression [173, 174].  
Compared with control individuals without sepsis, patients with sepsis have 
increased reactivation rates of latent viruses. Among populations of critically ill patients 
without sepsis, only 5% of the population expressed viral-DNA in their blood. By contrast, 
42% of critically ill sepsis patients expressed detectable viral DNA [172]. Autopsies of 
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human cadavers of patients with sepsis have shown the presence k persistent infection foci 
along with the presence of microabscesses in over 80% of the victims [175]. 
The downstream effects of persistent inflammation are numerous. of particular 
interest is a host immune environment similar to that of an elderly individual at baseline – 
i.e., inflammaging (constant low-grade inflammation in the aged) contributing to 
immunosenescence (the innate and adaptive dysfunction immune systems of the aged) 
[176, 177]. 
During sepsis, there are drastic changes in adaptive immunity. In response to 
cytokine and chemokine, production granulocytes often demarginate and follow the 
cytokine and chemokine trail. This denigration of granulocytes stimulates the HSCs in the 
Bone Marrow (BM), which are stimulated to produce Immature Myeloid Cells (IMC), 
which later differentiate and mature into lymphocytes, granulocytes, or dendritic cells. This 
emergency and rapid replenishment is termed “emergency myelopoiesis” [178-180]. At 
this stage, the production and recruitment of myeloid cells take precedence over the 
formation of lymphocytes and erythrocytes. This results in a deficiency of lymphocytes 
(lymphopenia) and the loss of thrombocytes, causing anemia [181, 182]. 
While normal conditions, these IMCs will mature into granulocytes, lymphocytes, 
or dendritic cells; septic shock elicits an intense storm pro-inflammatory cytokine-like, 
which prevents immature myeloid cells from differentiating and maturing. Instead, these 
IMCs form a heterogeneous population of immature myeloid cells called myeloid-derived 
suppressor cells (MDSCs) [183-186]. These MDSCs exhibits both inflammatory and 
immune suppressive properties. This is accompanied by the formation of an immature 
neutrophil (polymorphonuclear) phenotype [183, 186] accompanied by a loss of monocyte 
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inflammatory cytokine production and antigen presentation [185], following the ROS-
induced neutrophil recruitment caused by C5a. As these neutrophils lack any sufficient 
levels of Adhesin proteins from extracellular traps made up of DNA, Chromatin, or 
granular proteins, this inhibits them from exerting anti-microbial actions. The formation of 
MSDCs and the immature neutrophils are classic biomarkers that indicate sepsis and 
immunosuppression, as illustrated in animal models [186, 171]. 
During PICS, there is an overall decrease in the number of helper and cytotoxic T-
cells due to apoptosis and resistance towards pro-inflammatory cytokines [188]. Post-
mortem studies of patients who died of sepsis in intensive care units show a marked 
deficiency of CD4+ and CD8+ T-Cells in the lymphoid system. Other studies have shown 
decreased TNF and IL-6 production levels in response to endotoxins [188-190]. This role 
has been prominently linked with MDSCs. 
Poor clinical outcomes have been associated with the expansion of MDSCs, 
specifically after sepsis. Unlike other myeloid cell types, these MDSCs exhibit strong 
immunosuppressive properties. Even though the complete workings of MDSCs are not yet 
elucidated, MDSCs play a central role in propagating their anti-inflammatory effects even 
during times of sepsis and trauma. They are implicated in the inhibition of adaptive 
immunity for their role in downregulating the T-cells, B-cells, and APC populations. 
MDSCs are divided into two types: monocytic and granulocytic [191]. MDSCs carry out 
their immunosuppressive actions in a variety of ways based on their subtype [192]. Mathias 
et al. demonstrated that MDSCs are persistently increased in the circulation, predominantly 
granulocytic, transcriptomically unique, and immunosuppressive to T lymphocytes after 
severe sepsis or septic shock in the Surgical ICUs (SICU) [191]. Persistently increased 
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percentages of blood MDSCs in this study were associated with increased nosocomial 
infections, prolonged intensive care unit stays, increased mortality, low poor functional 
status at discharge [191]. 
While the Medical ICU (MICU) patients showed a higher population of monocytic 
and granulocytic MDSCs, granulocytic MDSCs (G-MDSCs) count was particularly 
prominent with sepsis patients. In addition, sepsis causes APCs to lose expression of the 
human leukocyte antigen-antigen D related (HLA-DR) and activating MHC type II. This 
molecule is associated with immune stimulation, and HLA-DR repression is associated 
with immunosuppression and is a predictor of unfavorable outcomes  during sepsis [190]. 
This HLA-DR REPRESSION combined with the increased surface expression of 
inhibitory T-cell ligands by APCs, promote promotes the release of anti-inflammatory 
along with a directional skew towards immunosuppressive TH2 phenotypes  
These immunosuppressive processes lead to the phagocytosis of apoptotic 
lymphocytes resulting in the release of anti-inflammatory cytokines such as IL-10 by APCs 
and the suppression of proinflammatory cytokine transcription [193]. These anti-
inflammatory cytokines upgrade the macrophages into a type II phenotype to upregulate 
T-regs. This is followed by the upregulation of arginase 1 (Arg1), which depletes arginase 
one. The G-MDSCs of sepsis patients exhibited high ARG1 activity, along with an 
increased expression of degranulation markers [194]. Along with ARG1, iNOS expression 
further impairs intracellular signaling and further promotes the apoptosis of T-cells. Then, 
nitric oxide, which arises as a byproduct of iNOS, then interacts with ROS generated by 
MDSCs, produces proximities. These peroxynitrites are used to nitrosylate several cell-
surface proteins on the lymphocyte and the cysteine residents. This makes the T-Cell 
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express decreased responsiveness and alters its IL-2 signaling. Furthermore, Nitric Oxide 
affects the stability of Il-2's mRNA, and ROS suppresses the functions of the natural killer 
(NK) cells. Finally, MDSCs induce T-regs and upregulate the programmed death ligand-1 
(PD-L1) by initiating direct contact through the CD40 receptor, while other checkpoint 
inhibitors in MDSCs cause T-cell apoptosis [192]. 
Lymphopenia occurs due to both acute apoptosis of effector T and B lymphocytes 
during sepsis, as well as the HSC shift to myelopoiesis [192, 195]. Lymphocytes also 
undergo TH2 polarization as well as the expansion of Treg cells. Neutrophilia occurs, but 
these effector, immature myeloid cells are suboptimal because they have a decreased 
capacity for antigen presentation, expression of adhesion molecules, and formation of 
extracellular traps, as well as an altered pattern of expression of cytokines and chemokines 
[193], coupled with low lymphocyte counts in the early days of sepsis, elucidate early 
lymphopenia as a biomarker for immunosuppression during sepsis [194]. Animal models 
that inhibit the sepsis-induced apoptosis of lymphocytes have shown increased survival 
rates. This data suggests the potential for therapies that focus on the inhibition of 






THE GENETICS OF SEPSIS 
 
The role of genetics in sepsis was first elucidated about 30 years ago when a study found 
out that adopted children expressed a fivefold increase in mortality rates when their 
biological parents (but not their adopted parents) died from infectious disease by the age 
of 50 years [201]. Further studies on sepsis and mortality have revealed a genetic aspect of 
human resistance or susceptibility toward sepsis/trauma outcome [205-212]. Recent 
genome-wide association studies have implicated gene polymorphisms that affected sepsis 
outcomes in all chromosomes, including the X chromosome (ChrX) [213-216]. The 
presence of gene polymorphisms in ChrX suggests that there might be sex-related 
differences in sepsis-outcome sepsis outcomes between men and women. This hypothesis 
is referred to as the nonhormonal hypothesis and states that the difference in sepsis-related 
outcomes is based on the differential homeostasis of the sex chromosomes. It is well-
known that adult women have more robust immune responses than adult men [205, 206-
214, 217, 218]. These data are supported by lower mortality rates among female sepsis 
patients than their male counterparts by almost 70% (27% vs. 46%; p = 0.048) [219]. As 
compared with their male counterparts, women express lower serum concentrations of 
cytokines during periods of critical inflammation. Women also express lower TNF levels, 
a critical biomarker of sepsis, whereas, in men, TNF levels continuously increase [220]. 
Furthermore, women also express higher levels of TLR7, which promotes macrophage 
recruitment and phagocytic activity. Dendritic cells also have greater type 1 IFN activity 
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[221]. Women also recruit higher numbers of antibodies, B-cells, CD4+ T-cells, and 
express lower numbers of T-regs [208, 209]. 
ChrX is rich in immunomodulatory genes. In contrast, the Y chromosome carries 
genes that predominantly govern sexual attributes in men with limited immunomodulatory 
effects [224]. Men inherit one copy of ChrX, whereas women inherit two copies of ChrX. 
One of these copies of ChrX is randomly inactivated (suppressed by methylation) during 
early embryogenesis as a mechanism to prevent increased protein production due to having 
two copies of ChrX [225]. This results in genetic mosaicism, which is the co-existence of 
cellular populations with different genotypes. This condition, unique to women, is thought 
to result in sex-biased differences in cellular phenotypes, as shown in Figure 4.1 [205, 217, 
224, 225]. Genetic polymorphisms of any of these ChrX immunomodulatory genes could 
potentially explain the sex-based immune responses seen in men and women.  
Many of the genes that are involved in sepsis are also involved in cytokine 
production through NF-κB stimulation and production. Genes that are involved in TLR 
signaling and innate immunity are found on ChrX, including IRAK-1, TLR7, TLR8, 
Bruton's kinase, and inhibitor of kappa B kinase gamma (NEMO). Hence, it is thought that 
the polymorphisms in the ChrX-linked key gene IRAK-1 could impact the TLR–NF-κB 




Figure 4.1  ChrX-induced cellular mosaicism as a result of protein variation induces 
phenotypic diversity in females and functional polarity in males. 
 
Source: Spolarics, Z., Peña, G., Qin, Y., Donnelly, R. J., & Livingston, D. H. (2017). Inherent X-linked 
genetic variability and cellular mosaicism unique to females contribute to sex-related differences in the innate 
immune response. Frontiers in immunology, 8, 1455. 
 
4.1 The Role of Gender in Sepsis 
Genetic polymorphisms can play in the innate immune response may have far-reaching 
clinical effects that could be expressed in both haploid men and diploid women, as one 
copy of ChrX gets suppressed by methylation in early development leading to ChrX 
mosaicism in the latter. While women have equal levels of maternal and paternal ChrX 
inactivation (XCI ratio) in their blood, the expressions of ChrX mosaic cell subsets in the 
tissues and organ structures can sometimes be skewed [228, 229]. This skewed distribution 
of mosaic ChrX inactivated cell subsets can manifest itself at any age in healthy ChrX-
heterozygotic women but often occurs more frequently in the elderly [229-231]. These 
skewed distributions are due to phenotypical and functional differences because of ChrX 
mosaicism. This mosaicism might manifest phenotypical dissimilarities between the 
subsets, which can lead to further ChrX skewing (conventionally, XCI ratio > 3) driven by 
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the unequivocal functional mechanisms of these mosaic subsets [231, 205]. For example, 
in heterozygotic women, differences in the functional pathologies between the mosaic stem 
cell subsets in the bone marrow [236] or mature WBCs at the periphery might further add 
to ChrX skewing [237]. 
During inflammation, acute ChrX cellular skewing toward a functional phenotype 
can occur as a product of differential cell trafficking and recruitment toward a site of injury 
or due to differential rates of necrosis, apoptosis, and cell proliferation driven by ChrX-
linked allelic traits. This de novo ChrX-based cellular skewing in the blood is temporary 
and reversible, as the original cell ratio is reestablished following recovery from injury and 
after the inflammation dissipates [205]. 
However, sometimes an inflammatory response can result in irreversible and 
permanent skew in the bone marrow cells. This condition has been observed in mice-
mosaic models of  CYBB (gp91phox) and IRAK-1 under endotoxic stress and has shown 
permanent skewing in the blood and immune-competent organs. These studies have also 
revealed this skew often promotes increased survivability compared to homozygous 
wildtype animals [233–235]. This phenomenon is also observed frequently among healthy 
women or amongst women with severe phenotypically defective ChrX-linked proteins and 
is marked by increased populations of one mosaic subpopulations compared to the rest to 
the other subpopulations [60-62, 236-238]. Compared to men, this increased variability 
and flexibility often represents an advantageous condition especially under times of severe 
immune-pathophysiological conditions. Furthermore, ChrX skewing is often a confounder 
in sex-based or genetic association studies because it may mismatch the expected 
genotype-phenotype relationships. Therefore, studies investigating biological processes 
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associated with ChrX-linked genes need to test whether ChrX skewing occurs in 
heterozygous women and, if so, whether it is tilted toward or against the genetic variant of 
interest [205, 217, 239]. 
       A. Classic ChrX Skewing      B. Acute ChrX Skewing 
 
Figure 4.2  Cellular skewing can be temporary or permanent. When driven by primary 
changes in bone marrow progenitors can result in irreversible skewing (A) versus 
temporary mosaic skewing at the periphery driven by X-linked allelic variants (B). 
Source: Spolarics, Z., Peña, G., Qin, Y., Donnelly, R. J., & Livingston, D. H. (2017). Inherent X-linked 
genetic variability and cellular mosaicism unique to females contribute to sex-related differences in the 
innate immune response. Frontiers in immunology, 8, 1455.  
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4.2 IRAK-1 Polymorphisms in Sepsis 
Given the importance of IRAK-1 in immune regulation, the differential skewing of ChrX 
in heterozygous women can lead to significant phenotypic changes that may alter the 
course and the intensity of their immune responses. IRAK-1 exhibits differential messenger 
RNA splicing variants, IRAK-1B and IRAK-1C, which are formed due to improper 
splicing of exons 11 and 12. IRAK-1A is considered the correctly spliced version of IRAK-
1. Meanwhile, the splice variant IRAK-1B expresses a shortened version of exon 12, 
whereas IRAK-1C completely lacks exon 11 (Fig. 4.3); overall, both these splice variants 
lack a functioning kinase domain. While the effects of both these splice variants are known, 
the full impact of a heterozygote with two different splice variants has not been elucidated 
yet [205, 217, 239]. 
’ 
Figure 4.3  Graphical representation of IRAK-1 splice variants. The top boxes represent 
exons, and the lines represent introns of IRAK-1 of 5’-154.0200 to 3’-154.0105 Mb. The 
stars on Exon 12 represent the SNP rs1069703.  
 
Source: Morcillo, P., Qin, Y., Peña, G., Mosenthal, A. C., Livingston, D. H., & Spolarics, Z. (2020). 
Directional X Chromosome Skewing of White Blood Cells from Subjects with Heterozygous Mosaicism for 
the Variant IRAK-1 Haplotype. Inflammation, 43(1), 370-381. 
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LPS stimulation and subsequent immunoblotting analysis of macrophages and 
dendritic cells revealed a decrease in IRAK-1A levels, suggesting protein degradation after 
activation, along with the induction of IRAK-1C expression. The data suggest that IRAK-
1C might play a role as a pro-inflammatory TIR signaling regulator, like IRAK-M. These 
data further support a novel theory that cells could fine-tune downstream inflammatory 
cascades/responses. This is done by selectively depleting IRAK-1A and replacing it with a 
functionally defective kinase, IRAK-1C, which provides a novel insight into TIR signaling 
mechanisms [246]. 
While Rao et al. studied the role of the splice variant IRAK-1C, recent research 
conducted by Spolarics et al. suggested the existence of ChrX skewing at sites of the 
immune organs under inflammatory conditions. Furthermore, Morcillo et al. observed 
ChrX-based skewing in IRAK-1A/IRAK-1C heterozygous women toward leukocytes 
lacking any immunomodulatory capabilities. This condition promotes improved sepsis 
outcomes similar to as observed in relation to IRAK-1 deficiency [239, 246]. 
Given the importance of the IRAK-1 gene and the transcriptomic effects that 
IRAK-1C plays in reducing inflammation, IRAK-1C can be viewed as a potential 
alternative-splicing therapy. Furthermore, understanding the exact nature of IRAK-1C can 
lead to the production of highly precise inhibitors that can seek to inhibit IRAK-1A, 
preventing sepsis temporarily [246].  
Apart from the splice variants, various single-nucleotide polymorphisms (SNPs) 
have been discovered in IRAK-1 that ensures significantly worse clinical outcomes during 
conditions of sepsis, trauma, cancer, and autoimmune diseases, like the SNP variant 
rs1059703 on exon 12, which is characterized by a thymine→ cytosine base pair change at 
 
40 
the 1674th base pair of exons 12, leading to the replacement of the amino acid leucine with 
serine at IRAK-1's kinase domain. This SNP is found only in the IRAK-1A and -1C splice 
variants, as IRAK-1B expresses a shortened form of exon 12 where the variant site is 
deleted, as shown in Fig. 4.3. 
The rs1059703 SNP is widespread among various ethnic and racial groups in a 1:4 
ratio, with 32% to 50% of heterozygotic women expressing WBC mosaicism for wildtype 
and variant alleles. Furthermore, this allele is found to exist in an almost perfect state of 
linkage-disequilibrium with five intronic SNPs (“rs3027898 T→G, rs731642 G→A, 
rs2239673 T→C, rs5945174 A→G, and rs7061789 A→G”), along with three more exon-
based SNPs “rs1059701 C→T (synonymous), rs1059702 C→T (nonsynonymous), and 
rs1059703 T→C (nonsynonymous)” [247]. Even though these SNPs exist in near-perfect 
LDE with an R2 value of almost 1.0, the importance of the rs1059703 haplotype, especially 
with the 532 L→S substitution, has been marked as a primary genotyping marker. Several 
studies have confirmed the marked negative impact of this haplotype, as it increases IRAK-
1 phosphorylation rates, causing an increase in TLR-mediated NF-κB pathway activation, 
resulting in higher levels of pro-inflammatory cytokine transcription and release. Animal 
and human models of LPS-induced sepsis have shown the accumulation of leukocytes and 
APCs in organ systems, together with the increased expression of downstream pro-
inflammatory cytokines and chemokines, owing to LPS-induced NF-κB translocation into 
the nucleus [248–252]. 
Further studies have identified and elucidated these LPS-induced NF-κB 
translocation patterns as critical biomarkers that enable the prediction of sepsis' clinical 
course. This prediction model has repeatedly proved vital, especially when assessing 
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patients who suffer from sepsis-induced ALI who express increased neutrophil levels. In 
these patients, LPS-induced ALI has also been associated with prolonged hospital stays, 
with extensive mechanical ventilatory support [253]. Patients with the variant IRAK-1 
haplotype had higher 60-day mortality than wildtype patients (53% vs. 30%; p = 0.05) 
[253]. The rs1059703 SNP has also been implicated in causing a general increase in CRP 
levels, a marker of inflammation, and a predictor of cardiovascular risk [254, 255] in 
diabetic Caucasian women, along with high levels of hypertension. 
While the SNP rs1059703 has been implicated as one with increased autoimmune 
effects, this SNP was also found to exert no effect on ALI, mortality rate, or ventilator-free 
days in the Han Chinese population. While authors have speculated that the increased 
prevalence of rs1059703 in the IRAK-1C allele in Han Chinese (87.5%) as compared with 
among Europeans (18.9%) might be the cause, this has not been confirmed yet [256]. This 
would be a crucial discovery that would confirm the role of IRAK-1C and the 
inflammation-induced skewing of ChrX cells among IRAK-1A/C heterozygotes as a 




METHODS OF DATA ANALYSIS  
 
5.1 Source of Data 
In order to study the transcriptional mechanisms of IRAK-1 and its splice variants and their 
combined effects with SNP rs1059703 mutant haplotype, we analyzed data from NCBI's 
SRA database containing RNA-seq data of human peripheral blood mononuclear cells from 
15 patients were taken. This study was conducted by Columbia University in 2016, with 
the Bio project ID PRJNA343985 and the Geodata set accession number GSE87290 [258].  
Based on data from previous studies, the contributors Ferguson and Xue selected 
only the individuals in the top (high-responders) and bottom (low-responders) extremes for 
inflammatory responses from previous studies. These patients were subjected to inpatient 
endotoxin challenge (1ng/kg LPS) in healthy humans. RNA-Seq was conducted for 
peripheral blood mononuclear cells (PBMC, n=15) before and after LPS administration. 
As previously stated, human monocyte cells predominantly expressed IRAK-1A, with 
minimum levels of IRAK-1C expression. This allowed the sensitive recording of changes 
in IRAK-1 mRNA levels [258]. 
 
5.2 Data Processing 
The experimental SRA runs from NCBI were aligned with the identifier sequences in table 
5.2 using SRA Blast. The total number of perfect matches was counted. These values were 
later normalized by dividing them by the number of Giga-base pairs (Gbp) of each SRA 
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read's data file to give a normalized value. This data was processed using Python, R, and 
Jupyter Notebooks for statistical calculations.  
Table 5.1  SRA Blast Query Sequences. These queries are oriented 5’ to 3’. The four 
underlined bases at the 5’ prime end represent Exon 12 in IRAK-1A and Exon 11 in IRAK-
1C. The rs1059703 SNP at the 3’ prime end is highlighted in bold. The combination of 
these two factors makes each oligonucleotide distinct. 













Source: Morcillo, P., Qin, Y., Peña, G., Mosenthal, A. C., Livingston, D. H., & Spolarics, Z. (2020). 
Directional X Chromosome Skewing of White Blood Cells from Subjects with Heterozygous Mosaicism 
for the Variant IRAK-1 Haplotype. Inflammation, 43(1), 370-381. 
 
5.3 Statistical Processing and Data Analysis 
All statistical analyses were performed in Jupyter notebooks using python. The Shapiro 
test for normalcy to determine the normalcy of the variables under study and, secondly, 
subjectively by observing the histograms and box plot outputs [259]. To determine if there 
were significant differences between two groups of paired data, we performed a paired-T-
test for parametric data [260] and a Wilkson-paired-T-test [261] for nonparametric data 
based on the Shapiro test results. Similarly, for unpaired and independent data, we 
conducted an independent t-test to compare two parametric samples and the Mann-Whitney 
U test for comparing two groups and the Kruskal-Wallis test while comparing more than 
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two groups with each other [261, 262]. When the Kruskal-Wallis test showed significance, 








6.1 Data Demographics 
The dataset reported by Ferguson & Xue contains 30 samples from 15 patients reporting 
the SRA transcript sequences before and after endotoxin challenges. This dataset has data 
from 8 males and 7 females, with Caucasian (n = 9) and African American (n = 6) ethnic 
backgrounds. The authors had also categorized these patients into two groups of high and 
low inflammation, based upon the participant’s previous sensitivity to the endotoxin 
challenge and the magnitude of their immune responses [255]. 
We used the search queries from table 5.1 with the SRA blast algorithm to 
determine the genotypes of the participants in this dataset and reported the results in Table 
6.1. Our findings report the presence of 5 different genotypes expressed among the 
population. The genotypes reported are homozygotes for IRAK-1 (WT), IRAK-1 
homozygotes expressing the rs1059703 SNP mutation, termed as “IRAK-1 (Var)”, along 
with heterozygotes with IRAK-1 (WT) / IRAK-1 (Var) genotypes. The counts are reported 




Table 6.1  Demographics of the Sample Dataset 
 Males (n) Females (n) Total 
Total Participants 8 7 15 
    
Ethnicity    
Caucasian 6 3 9 
African American 2 4 6 
    
Inflammation response:    
High 4 4 8 
Low 4 3 7 
    
By Genotypes:    
    
Homozygotes   11 
IRAK-1 (WT) Homozygote 5 2 7 
IRAK-1 (Var) Homozygote 3 1 4 
    
Total Heterozygotes (WT/VAR) - 4 4 
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6.2 Exposure to LPS Causes a Reduction of IRAK-1 mRNA Expression 
While the roles of cytokines in inflammation have been extensively studied, the genetics 
of their regulatory molecules have not from the transcriptomic point of view. Recent 
studies on inflammatory responses have shown that differential gene expression can lead 
to changes in the inflammatory response, primarily through variances in mRNA levels. To 
detect changes in the mRNA levels, we compared the total IRAK-1 expression levels 
before (Median = 2.7) and after the LPS (Median = 1.8) treatment. We tested for normalcy 
using the Shapiro-Wilk test, which showed that the data was not normally distributed. 
Hence, we conducted nonparametric tests. The Wilcoxon paired test indicated that there 
was a significant difference between the median of the two groups with p= 0.005 (Fig. 
6.1A). 
We performed a linear regression analysis with the IRAK-1 levels before LPS 
treatment against the expression levels after LPS administration to see if the decrease in 
IRAK-1 level is proportional to IRAK-1's baseline levels. The linear model had an R2 value 
of 0.31 and a slope of 0.74, with an intercept of -0.249. This data suggests that the changes 
in IRAK-1 levels following LPS treatment are significant but are primarily dependent on 








Figure 6.1  LPS administration reduces IRAK-1A expression levels. (A) Boxplot shows 
the overall IRAK-1A expression levels before and after LPS treatment. (B) Linear 




6.3 Exposure to LPS Does Not Elicit Any Significant Changes in IRAK-1C mRNA 
Levels 
To investigate the effects of IRAK-1 splice variants on IRAK-1’s expression levels, we 
compared IRAK-1A and IRAK-1C expression levels before and after LPS treatment. We 
used the Wilcoxon signed-rank test to assess the impact of LPS on IRAK-1A and IRAK-
1C levels (Fig. 6.2 A & B). Our results indicated a significant decrease in IRAK-1A levels 
(p=0.006) following administration of LPS (Median = 1.74, SD = 3.52) compared to 
baseline (Median = 2.93, SD = 3.92) conditions. Furthermore, we did not find any 
significant differences in the IRAK-1C levels (p = 0.7) between baseline (Median = 0.06, 
SD = 0.13) and LPS conditions (Median = 0.04, SD = 0.08).  
We conducted linear regression analyses on IRAK-1A and IRAK-1C levels to 
determine if IRAK-1A and IRAK-1C levels after LPS treatment are dependent on their 
initial levels. (Fig. 6.3). The IRAK-1A model had an R2 value of 0.31 and a slope of 0.76, 
with an intercept of -0.34. The IRAK-1C model had an R2 value of 0.0016, with an intercept 
of 0.73 and a slope of -0.13. This data suggests that only the splice variant IRAK-1A’s 
expression is affected by endotoxin challenge, and IRAK-1C levels are not affected by 





Figure 6.2  Changes in IRAK-1 levels are due to a decrease in IRAK-1A levels. While 
IRAK-1A levels decrease upon LPS treatment (A) whereas, IRAK-1C expression does not 




6.4 The Role of IRAK-1 in Hyperinflammation 
A variety of studies have sought to understand the dynamics of the TLR-NF-κB pathway 
in inflammation as an attempt to develop possible therapies aimed at restoring cytokine 
regulation in sepsis. These studies often implicate IRAK-1 as a critical mediator in 
regulating the intensity of endotoxin challenges. High levels of IRAK-1 expression have 
been associated with increased pro-inflammatory activity, whereas studies on LPS-
tolerance in human monocytes revealed unaltered TLR4 expression but suppressed 
MyD88-TLR4 and IRAK-1-MyD88 interactions, IRAK-1 activation. This might be due to 
a regulatory mechanism that is induced by miRNA-146A. 
In order to compare the differences in IRAK-1 mRNA expression between groups 
with low and high inflammation levels, we used the paired t-test to check for significant 
differences among the means for IRAK-1A, IRAK-1C, and the total IRAK-1 expression 
levels. The Paired T-tests indicated a significant decrease in the IRAK-1 expression 
following LPS treatment in both the groups. The group with low inflammation had a p = 
0.03 (Baseline: Mean = 2.23, SD = 1.81 vs LPS: Mean = 1.42, SD =1.66) and the group 
with high inflammation reported a p = 0.0053 (Baseline: Mean = 6.02, SD = 4.66 vs LPS: 
Mean = 4.21, SD = 4.22). As IRAK-1A levels are primarily responsible for changes in the 
total IRAK-1 levels, it also showed significant differences in both high (p=0.01, Baseline: 
Mean = 5.91, SD = 4.55 vs LPS: Mean = 4.12, SD = 4.42) and low inflammation groups 
(p=0.01, Baseline: Mean = 2.17, SD = 1.76). Similar to our previous results, IRAK-1C 
failed to show any significant differences for neither the high (p =0.86 Baseline: Mean 
=0.11, SD = 0.178 vs LPS: Mean = 0.088, SD = 0.097) or the low inflammation groups (p 
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= 0.85) Baseline: Mean = 0.57, SD = 0.052 vs LPS: Mean =0.038, SD = 0.060). (Refer 
Table 6.2 for detailed descriptive statistics)  
6.4.1 Increased Baseline IRAK-1 Expression Levels Before Endotoxin-Induced 
Stress Are Associated with Hyperinflammation  
To quantitatively analyze and understand the impact of IRAK-1 in endotoxin sensitivity, 
we compared IRAK-1 levels before and after the administration of LPS between two 
groups of low and high inflammation. Our results indicated the high inflammation group 
(Median = 6.02, SD = 4.66), compared to the low inflammation Group (Median = 
2.23, SD = 1.81), had higher levels of IRAK-1, with p = 0.036. We observed a similar trend 
in IRAK-1A as well, where the high inflammation group (Median = 5.91, SD = 4.55) 
expressed increased IRAK-1A levels with a similar p-value of 0.036. However, when we 
performed the nonparametric Mann-Whitney test, we did not see any significant 
differences between the IRAK-1 levels of the low (Median = 0.66, SD = 1.16) and high 
(Median = 2.82, SD = 4.42) inflammation groups, with p = 0.136. IRAK-1A followed suit 
with p=0.138 for IRAK-1A levels between high (Median = 2.625, SD = 4.42) vs. low 
(Median = 0.620, SD = 1.13). Consistent with previous tests, IRAK-1C did not exhibit any 
significant changes (Fig. 6.3).
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Table 6.2  Descriptive Statistics of IRAK-1 Expression Levels Before and After LPS 
Treatment for High and Low Inflammation Groups 
 Treatment Response Group Mean Median Std Dev Variance 
IRAK-1A Baseline High 5.91 5.025 4.554 0.480 
  Low 2.17 1.330 1.762 0.811 
 Intravenous 
LPS 
High 4.128 2.625 4.429 19.619 
  Low 1.366 0.620 1.132 1.280 
IRAK-1C Baseline High 0.110 0.06 0.178 0.032 
  Low 0.057 0.04 0.053 0.004 
 Intravenous 
LPS 
High 0.083 0.05 0.098 0.009 
  Low 0.039 0.02 0.061 0.003 
IRAK-1 
Total Baseline High 6.020 5.025 4.660 21.720 
  Low 2.227 1.370 1.812 3.285 
 Intravenous LPS High 4.210 2.82 4.422 19.554 





                     A.                                                                                B. 
 
.                                                            C.  
 
Figure 6.3  Patients with high inflammatory levels express higher IRAK-1 and IRAK-1A expression before LPS treatment. (A) 
There is a significant decrease in IRAK-1 (A) and IRAK-1A (B) following LPS treatment in expression levels. (C). There is no 





We hypothesized that this might be due to increased phosphorylation of IRAK-1A, 
promoting inflammation via cytokine release. Hence, we compared the changes elicited of 
LPS-induced toxicity between high and low inflammation groups by comparing the 
differences in IRAK-1A, IRAK-1C, and the total IRAK-1 levels (Table 6.3). Surprisingly, 
there were no significant differences in IRAK-1 levels p=0.36 in the changes elicited upon 
the IRAK-1 levels between the low (Median = 0.01, SD = 0.234) and High inflammation 
(Median = 0.1, SD = 0.06) groups.  
Table 6.3  Descriptive Statistics of Changes in IRAK-1 Expression Following LPS 
Treatment 
 Inflammatory response Mean Median Std Dev Variance 
IRAK-1A 
High -1.810 -1.18 2.826 7.986 
Low -0.823 -0.43 1.007 1.014 
IRAK-1C 
High -1.783 -1.19 2.684 7.203 
Low -0.804 -0.41 0.986 0.972 
IRAK-1 
(Total) 
High -0.028 0.01 0.234 0.055 
Low -0.019 -0.02 0.065 0.004 
 
 
6.5 The Role of IRAK-1C in Hyperinflammation 
Past studies have shown that the rs1059703 SNP variant is linked to unfavorable outcomes 
in sepsis. In order to understand the combined effects of the splice variant along with the 
SNPs on inflammation, we compared the changes in the overall IRAK-1 expression levels 
for the WT or Var homozygotes and the WT/Var heterozygotes (Fig. 6.4).  
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As the rs1059703 SNP variant is associated with increased inflammation, and the 
IRAK-1C splice variant is a dominant-negative variant that suppresses inhibition, we 
hypothesized that there would be a significant difference in the total IRAK-1 levels 
between the homozygous IRAK-1 variants and both the homozygous IRAK-1 (WT) and 
the heterozygote groups. The results of the Kruskal-Wallis test (F = 13.429, p = 0.001) 
show that there was at least a significant difference in at least one of the groups. Consistent 
with our hypothesis, the post hoc Mann-Whitney test showed that there was a significant 
difference) between the homozygous variants (Median = 8.09, SD = 4.045) and the 
heterozygotes (median = 2.035, SD = 3.214) with p = 0.003. We also noticed a significant 
difference (p = 0.005) between the homozygous variants and the homozygous WTs 
(median = 1.180, SD = 2.025). However, we did not notice any differences between the 
homozygous WTs and heterozygotes.  
We also noticed a significant difference between the three groups when we 
compared the IRAK-1 levels before (F = 7.525, p = 0.023) and after LPS treatment (F = 
6.225, p = 0.044). The results from the post hoc Mann-Whitney test before the LPS 
treatment were similar to the results from the overall data and are shown in Figure 6.5. We 
noticed that there were significant differences between the homozygous variants and the 
heterozygotes (median = 2.035, SD = 3.215) and also between the homozygous variants 
(median = 8.090, SD = 4.045) and WTs (median = 1.370, SD = 2.109) before LPS treatment 
(Fig. 6.5A). This data suggests an increased IRAK-1 expression prior to LPS 
administration among the homozygous variants and is consistent with previous findings 
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Figure 6.4  Comparative expression of IRAK-1 and its splice variants between Homozygous WTs, Homozygous Variants and 







Figure 6.5  Heat map analysis of the IRAK-1 levels from the Kruskal-Wallis test followed 
by the post hoc Mann-Whitney (p < 0.05) between Homozygous WTs, variants, and the 
Heterozygotes (WT/Var) before (A) and after LPS treatment (B). 
 
Furthermore, we also noticed a significant difference between the three groups 
when we compared the IRAK-1 levels in groups of low inflammation (F =10.250, p = 
0.005) but not amongst patients with high inflammation and after LPS treatment (F = 6.225, 
p = 0.044). The results from the post hoc Mann-Whitney test for patients with low 
inflammation showed a significant difference between the homozygous variants (median 
= 10.270, SD = 3.398) and heterozygotes (median = 1.305, SD = 1.055) (p = 0.028), 
between the homozygous variants and the homozygous WTs (median = 2.700, SD = 2.276) 
(p = 0.024). However, we did not find any significant differences between the 




Figure 6.6  Heat map analysis of the IRAK-1A from the Kruskal-Wallis test followed by 
the post hoc Mann-Whitney (p < 0.05) between Homozygous WTs, variants, and the 
Heterozygotes (WT/Var) for patients with low inflammation. 
 
As the SNP the rs1059703 is implicated with increased inflammation, we compared 
the IRAK-1A (Var) levels amongst the groups. The results from our Kruskal-Wallis 
analysis show that there were significant differences in the overall IRAK-1C levels 
between the heterozygotes and the homozygous variants groups before (p = 0.015) and 
after (p = 0.015) LPS treatment. We find an increased expression of IRAK-1A (Var) in 
homozygous variants before (median = 9.945, SD = 3.528) and after LPS treatment 
(median = 6.395, SD = 4.633) when compared to the heterozygotes (Baseline: median = 
1.000, SD = 0.907; LPS: median = 0.655, SD = 0.615). Furthermore, we did not detect a 
significant difference in the IRAK-1A (Var) between the homozygous variants and the 




In order to investigate the effects of the rs1059703 SNP on the IRAK-1C splice 
variant, we compared the IRAK-1C, IRAK-1C (WT), and IRAK-1C (Var) levels between 
the three groups. Based on the results, we did not notice a significant difference in the 
overall IRAK-1C levels between the three groups (F = 5.490, p = 0.064). We were able to 
find a significant difference when we compared the IRAK-1C levels before and after LPS 
treatment, we found a significant difference in the IRAK-1C levels before LPS treatment 
(F = 7.300, p = 0.026) and we did not find any significant differences in the IRAK-1C 
levels post-LPS-treatment (F = 1.167, p = 0.55). Post hoc Mann-Whitney analysis of 
IRAK-1 levels before LPS treatment show that there was a significant difference between 
the homozygous WTs (median = 0.02, SD = 0.32) and the homozygous variants (median 
= 0.075, SD = 0.056) (p = 0.024). We did not find any difference between the heterozygotes 
(median = 0.05, SD = 0.136) and the homozygous WTs (p = 0.101) and between the 
homozygous variants and the heterozygotes (p = 0.245). We further investigated this by 
comparing the IRAK-1C (WT) and the IRAK-1C (Var) levels between the three groups.  
When we compared the IRAK-1C (WT) levels before and after LPS treatment 
between the three groups, we did not find any significant differences in the IRAK-1C (WT) 
levels between the three groups before (F = 3.248, p = 0.197) or after LPS treatment (F = 
3.972, p = 0.137) low. While we did not find any difference amongst the three groups in 
patients with high inflammation (F = 1.498, p = 0.473), we found significant differences 
amongst patients with low inflammation (F = 7.395, p = 0.025). The results from the post 




Figure 6.7  Heat map analysis of the IRAK-1C (WT) from the Kruskal-Wallis test followed 
by the post hoc Mann-Whitney (p < 0.05) between Homozygous WTs, variants, and the 
Heterozygotes (WT/Var) patients with low inflammation.  
 
To understand the impact of the IRAK-1C splice variant with the rs1059703 SNP 
on inflammation, we compared the levels of IRAK-1C (Var) before and after LPS 
treatment for heterozygotes and homozygous variants. However, we did not find any 
significant differences between the heterozygotes and homozygous variants before (p = 
0.055) and after (p = 0.5) LPS treatment. Furthermore, we also did not find any significant 
differences between the two groups amongst patients of low (p = 0.226) or high (p = 0.308) 
levels of inflammation. Thus, our data finds IRAK-1C with the rs1059703 mutation does 







7.1 Analysis of Results 
Sepsis is a complex, life-threatening condition that arises from a severely dysregulated 
immune response to infection. This dysregulated immune response can lead to a state of 
simultaneous chronic inflammation, and immunosuppression termed PICS, which can lead 
to multiple organ failure resulting in death. 
Innate immunity is primarily mediated by toll-like receptors. These receptors 
recognize pathogen-associated molecular patterns and initiate inflammatory responses 
primarily through the TLR-NF-κB pathway. This pathway is mediated mainly by the IRAK 
family of kinases, which are crucial mediators of inflammation. IRAKs play a 
multifunctional role in IL-1R signaling, TLR-based PAMP recognition, and the 
propagation of downstream-inflammatory signals via the NF-κB pathway. NF-κB has been 
identified as a critical propagator in inflammation due to its role in initiating the 
transcription of inflammatory proteins and cytokines [11-16]. There have been extensive 
studies linking the expression levels of both NF-κB and IRAK-1 to sepsis. Increased levels 
of IRAK-1 have been associated with increased inflammation due to an overproduction of 
inflammatory cytokines through the NF-κB pathway.  
Past studies have implicated a correlation between IRAK-1 and NF-κB pathways 
in sepsis. Past studies indicate an increased activation of NF-κB in alveolar macrophages, 
PBMCs, and neutrophils in sepsis patients. Increased expression of NF-κB is also 
correlated with increased levels of downstream pro-inflammatory cytokines such as TNF, 
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IL-1, IL-6, IL-8, and IL-12. These pro-inflammatory cytokines are crucial mediators of 
immune responses and are responsible for the recruitment of leukocytes to the site of 
infection. Furthermore, they also promote vasodilation and increase the permeability of the 
endothelial layers at the site of the infection to enable the extravasation of leukocytes into 
the site of the injury.  
While the expression of these pro-inflammatory cytokines is tightly regulated under 
normal conditions, sepsis causes an overwhelming and extremely dysregulated immune 
response that causes an overwhelming release of pro-inflammatory cytokines that lead to 
adverse effects such as endothelial dysfunction and damage to the peripheral tissues by 
promoting vasodilation and vasopermeability of the endothelial layers. This results in the 
leakage of cytokine-rich fluid into the periphery, causing edema and compromising the 
vascular volume and blood pressure. This comprises the overall blood circulation resulting 
in hypoxia. Furthermore, the increased cytokine activity from the increased cytokine 
activity promotes the recruitment of leukocytes and their extravasation into the peripheral 
tissues while stimulating them to produce secondary pro-inflammatory mediators. This 
leukocyte accumulation coupled with the lack of a functional endothelial layer allows 
pathogens to invade deeper into the host’s tissues, resulting in the positive feedback loop 
that promotes hyper inflammation and tissue damage that can potentially disturb 
homeostasis mechanisms and ultimately cause dysfunction of remote organs, through the 
combined and reciprocal actions of inflammation and hypoxia [103].  
A plethora of studies has shown that IRAK-1 and NF-κB levels correlate with 
crucial markers of sepsis, and sepsis-induced MODs like myocardial depression (CRP), 
ARDS (neutrophils), and Ischemic Hepatitis (CRP), confirming their roles as critical 
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moderators of inflammation and sepsis-based multi-organ failure. This makes IRAK-1 a 
crucial regulator of inflammation.  
Upon its activation by TIRs, IRAK-1 undergoes phosphorylation and is degraded 
by the ubiquitin-proteasome pathway [12]. Current results suggest a significant decrease 
in IRAK-1 mRNA expression levels following administration of intravenous LPS (Fig. 
6.1A). However, subsequent results show a linear correlation between total IRAK-1 levels 
before and after the administration of LPS (Fig. 6.2), suggesting that the initial levels of 
IRAK-1 before exposure to PAMPs/DAMPs determine the levels IRAK-1 after the LPS 
treatment. IRAK-1 levels are primarily dependent on the levels of inflammation. While 
this model has a poor fit, most of the variation in Figure 6.1 is explained by changes in the 
expression levels of IRAK-1A, the wildtype splice variant levels, as illustrated in Figure 
6.2C. 
On the other hand, there are hardly any changes in the levels of IRAK-1C. IRAK-
1C fails to contribute towards changes in the overall IRAK-1 Levels. This splice Variant 
has been associated with significantly lower neutrophils extravasation in ARDS and 
minimal levels of NF-κB and TNF activation. This splice variant is a dominant-negative 
and has been proposed a role that is similar to IRAK-M. It is thought to be a novel regulator 
of inflammation that prevents the conduction of downstream inflammatory signals. 
Consistent with their findings, we also fail to report significant changes in IRAK-1C levels 
upon LPS administration [246] (Fig. 6.2 B, D). 
To investigate the role of IRAK-1 and its splice variants in endotoxin-sensitivity 
and hyperinflammatory responses, we compared the levels of IRAK-1 and its splice 
variants before and after LPS treatment among groups of high and low inflammation. 
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While there were no significant changes in IRAK-1-C, IRAK-1A levels and the overall 
IRAK-1 levels did vary significantly. When we compared the levels of IRAK-1, IRAK-A, 
and IRAK-1C levels before and after LPS treatment, between groups of high and low 
inflammation, we noticed that while patients with high inflammation expressed higher 
levels of IRAK-1 and IRAK-1A mRNA, before LPS treatment, we failed to notice any 
significant differences in the IRAK-1 and the IRAK-1A after the administration of LPS 
between the groups of high and inflammation. These results suggest that the magnitude of 
inflammation depends on IRAK-1 levels before the endotoxin challenge and is consistent 
with previous studies on IRAK-1 and LPS tolerance.  
Past studies have implicated a decrease in the IRAK-1 mRNA levels with increases 
in microRNA-146a (miRNA-146a) expression. This miRNA is produced as a result of NF-
κB and hinders IRAK-1 mRNA expression through the RNA-interference pathway [263]. 
Past studies show that the miRNA-146a levels are continuously elevated for 24 hours in T-
helper cells following LPS administration. However, the exact role and mechanisms of 
miRNA146 and its relationship with TLR signaling has not been elucidated yet [264, 265]. 
When compared to adult men, women generally express more robust and regulated 
immune responses [205, 207-209, 217, 218]. Past studies have shown that women patients 
with sepsis express significantly lower mortality rates by almost 70% compared to their 
male counterparts [220]. This is thought to be a result of ChrX skewing. ChrX is rich in 
immuno-modulatory genes such as IRAK-1, TLR-4, TLR-7, TLR-8, NF-κB, and TNF. As 
men only inherit one copy of ChrX, any mutations or alterations to the ChrX genes can 
have disastrous consequences. However, in females, one of the copies of ChrX is randomly 
repressed to prevent increased protein production, resulting in genetic mosaicism [205]. 
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Recent research by Morcillo et al., [266] and Spolarics et al., [205] have shown a 
directional skewing among IRAK-1A/ IRAK-1C heterozygous that results in up-regulation 
of WBCs and immune cells expressing IRAK-1-C. This skew might explain why women 
express healthier and more balanced inflammatory responses than men under conditions of 
persistent inflammation. These studies are consistent with Rao et al.’s [246] findings on 
IRAK-1C that proposes an increase in IRAK-1C to IRAK-1A expression, thereby 
obstructing the activation of downstream inflammatory cascades.  
In order to investigate the effects of IRAK-1 splice variants and the SNP rs1059703 
on inflammation, we compared the levels of total IRAK-1 expression between the 
homozygous WTs, homozygous variants, and heterozygotes expressing both WT/Var. Our 
analysis indicated no significant differences in the overall IRAK-1and IRAK-1 expression 
levels between the homozygous WTs and heterozygous variants. However, the 
homozygous variants expressed significantly higher levels of IRAK-1 and IRAK-1A 
compared to both the homozygous WTs and variants. This data suggests the inhibitory role 
of IRAK-1C splice variants, despite the presence of rs1059703 amongst some of the 
heterozygotes.  
When we compared the levels of IRAK-1A (Var) in sepsis, we noticed extremely 
high levels of IRAK-1A (Var) before and after LPS treatment. To our surprise, we did not 
find any significant differences in the IRAK-1A (Var) levels following LPS treatment. 
Previous studies show no significant differences in the levels of miRNA-146a between the 
IRAK-1 WTs and the IRAK-1 Variants. However, this SNP associated is an increase in the 
NF-κB levels [264-265]. In lieu of current findings, we think that there might the presence 
of hidden transcriptional regulatory mechanism that can control the levels of IRAK-1 
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mRNA expression. However, it does not seem to be affecting the IRAK-1A splice variant 
with the rs1059703 SNP. This might explain the constant state of inflammation expressed 
by IRAK-1A (Var) patients. 
 
7.2 Limitations and Future Considerations 
One of our primary concerns with this study is the small number of participants analyzed. 
Due to a lack of sufficient processing capability and time constraints, we could only 
analyze a small dataset with 15 participants and 30 data points. Due to the sample’s small 
size, our data might not have strong resolving power and can result in type-II errors, where 
the null hypothesis is false and fails to get rejected [267]. We strongly feel that this issue 
might be particularly relevant regarding the IRAK-1C expression levels, given the 
variable's small effect on the total IRAK-1 levels. Therefore, the small sample size of this 
dataset might not possess the (statistical) power to expose such a small effect, possibly 
resulting in a type-II error. This limitation might also explain why we failed to notice 
significance while comparing the changes in IRAK-1 levels upon LPS administration 
between high and low inflammation groups. Furthermore, this sample set only includes 
patients of Caucasian and African American ethnicities and fails to consider the impact of 
age. Thus, this dataset would not be representative of the entire population.  
In our future studies, we would like to implement an automated cloud-based system 
capable of blasting huge SRA datasets containing data from a wide variety of patients with 
diverse ethnic backgrounds and ages.  
Furthermore, while there have been a plethora of studies investigating the role of 
IRAK-1A (with and without the rs1069703 SNPs) and their downstream effects in 
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inflammation, there is a scarcity of background data on the IRAK-1C mutant. Hence, we 
believe that it is prudent to measure the levels of downstream cytokines and relate the 
expression levels to the levels IRAK-1. This data will help elucidate the effects of the 
IRAK-1C splice variant and help correlate it with a wide range of markers.  
 
7.3 Conclusion 
Sepsis is a complicated condition that is characterized by highly dysregulated immune 
responses. These immune responses are generated through the activation of the NF-κB 
pathway, which is primarily governed by the adaptor molecule IRAK-1. A plethora of 
studies has elucidated the role of IRAK-1 and NF-κB in inflammation and sepsis-induced 
organ failure. Increased IRAK-1 expression has been associated with increased levels of 
crucial markers of sepsis such as C-Reactive proteins, decreased miRNA-146a levels, 
increased expression of hypoxia-induced genes, bilirubin, and blood lactic acid levels. 
Despite the plethora of evidence linking IRAK-1 in inflammation and hinting its role as a 
potential therapeutic target, there has not been much research conducted on the biochemical 
dynamics and mechanisms of its dominant-negative splice variant IRAK-1C.  
In this paper, we reviewed the wide spectrum of downstream effects exerted by 
IRAK-1 and sought to understand the combined effects of the IRAK-1A and IRAK-1C 
splice variants along with the proinflammatory rs1059703 SNP mutant on inflammation. 
We characterized inflammation based on the total mRNA levels IRAK-1. Our results show 
a paradoxical decrease in the IRAK-1 mRNA levels following LPS administration. This 
phenomenon might be associated with the effects of miRNA-146a, a negative regulator of 
 
69 
IRAK-1 mRNA expression. We also report that patients with a high sensitivity to LPS 
express higher levels of IRAK-1A prior to endotoxin exposure. 
Our results show a lack of significant differences in the overall IRAK-1 and the 
IRAK-1A levels amongst IRAK-1 (WT) homozygotes and the WT/Var expressing 
heterozygotes. We also noticed that there was a significant increase in IRAK-1 and IRAK-
1A levels among the homozygous variants compared to the homozygous WTs and the 
heterozygotes. As past studies have associated increased levels of IRAK-1 and IRAK-1A 
with hyper inflammation, our results are consistent with previous findings that implicate 
the IRAK-1A (Var) with increased inflammation and the dominant-negative effects of 
IRAK-1C inhibiting inflammatory activities. However, we did not find any significant 
decrease in IRAK-1A (Var) levels of heterozygotes upon LPS administration. While many 
studies have associated this haplotype with increased NF-κB levels, recent research has 
shown that this haplotype does not exhibit a significant increase in miRNA-146a levels 
compared to the IRAK-1A (WT). These results suggest that miRNA-146a might not be 
able to inhibit or negatively interfere with IRAK-1A (Var) mRNA expression.  
While our statistics also report any significant impact exerted of IRAK-1C (WT) 
and IRAK-1C (Var) between patients with low and high inflammation, we believe that the 
size of our dataset might have compromised the dataset’s resolving power to successfully 





SUPPLEMENTAL DATA AND CODE  
This appendix contains links to the complete dataset and the Python & Jupyter code used 
in the analysis.  
 
A.1. Data Source Used in Analysis  
The complete SRA Dataset used for analysis is available online on NCBI: 
https://www.ncbi.nlm.nih.gov/sra?term=SRP090337 
 
A.2 Code for Statistical Analysis 
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